Immatics N.V. (IMTX)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Net income
- -196,447,000 -1390.9%
- Operating income
- -182,016,000
- Earnings per share
- -1.61 -1250%
- R&D expense
- 183,832,000
Growth and profitability
- Return on equity
- -40.58
- Return on assets
- -34.93
Balance sheet
- Total assets
- 562,337,000
- Shareholders' equity
- 484,099,000
- Cash and equivalents
- 345,918,000
- Current ratio
- 11.72
Cash flow and ratios
- Operating cash flow
- -176,626,000
- Free cash flow
- -183,184,000
Shareholder returns
- Shares outstanding
- 134,071,432
- Book value per share
- 3.61
Company information
- Headquarters
- Tubingen, 2M
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
Immatics N.V. trades on NASDAQ under the ticker symbol IMTX. This page brings together its price chart, company profile, key financial figures and technical indicators.